Skip to main content

Detail

Bernd Jilma
Bernd Jilma, MDVice Chair

Department of Clinical Pharmacology
Position: Associate Professor

T +43 1 40400 29900
bernd.jilma@meduniwien.ac.at

Further Information

Keywords

Anaphylaxis; Biosimilar Pharmaceuticals; Clinical Trial, Phase I; Drug Interactions; Endotoxemia; Research Design; Therapeutic Uses

Research group(s)

  • Haematology & Immunology

Research interests

Our focus is to test newly developed drugs in sytemic or lung inflammation and hematologic patients. We combine in vitro, ex vivo and in vivo studies to obtain an integrated insight into pathophysiologic processes and pharmacodynamic actions of a drug. We have a strong background and interest in orphan diseases such as anaphylaxis, thrombotic thrombocytopenic purpura and currently cold agglutinin disease. We are specialised in innovated trial design including integrated study protocols and basket trial designs including first-in-human trials.

Techniques, methods & infrastructure

The department has got a phase I unit with 10 beds, where we perform first-in-human trials with biologics and small molecules, as well as phase I-III randomized controlled trials. We have established the human endotoxemia model to study drugs in systemic inflammation both for industry and academic purposes. Likewise we have established the endotoxin instillation into lungs in humans to investigate compartimentalized inflammatory responses and drug action. Platelet function tests including the platelet function analyzer and the multiple electrode aggregometry have been utilized in drug-drug interaction studies recently, where pharmacokinetics have been determined by tandem mass spectrometryThrombelastometric measurements and in vivo thrombin generation markers have been used for dose finding of novel anticoagulants and to examine specific pathophysiological changes. Flow-cytometry is used mainly to characterize in vivo changes of cellular blood components under drug treatment or inflammation.

Grants

  • Cellular Mediators Linking Inflammation and Thrombosis (project part leader) (2013)
    Source of Funding: FWF (Austrian Science Fund), Special Research Programmes (SFB54)
    Principal Investigator

Selected publications

  1. Peyvandi, F. et al., 2016. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med, 374(6), pp.511-522. Available at: http://dx.doi.org/10.1056/NEJMoa1505533.
  2. Kubica, J. et al., 2015. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. European Heart Journal, 37(3), pp.245-252. Available at: http://dx.doi.org/10.1093/eurheartj/ehv547.
  3. Ramsauer, K. et al., 2015. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. The Lancet Infectious Diseases, 15(5), pp.519-527. Available at: http://dx.doi.org/10.1016/S1473-3099(15)70043-5.
  4. Hobl, E.-L. et al., 2014. Morphine Decreases Clopidogrel'
  5. Tauber, E et al 2007. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet. 2007 370(9602):1847-53.